Investigating the effect of consuming calcium-enriched bread on markers of bone formation and resorption in diabetic patients

Effects of bread fortified with eggshell powder on anthropometric indices, glycemic status and markers of bone formation and resorption in patients with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190908044730N3

Enrollment

Registered

2023-02-12

Start date

2023-05-05

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes. Diabetes mellitus due to underlying condition

Interventions

Intervention group: The desired intervention is bread enriched with eggshell. This product, which is made with wholemeal flour, has an approximate weight of 75 grams, of which 5% is completely powdere

Eligibility

Sex/Gender

All

Age

40 Years to 65 Years

Inclusion criteria

Inclusion criteria: Consent to participate in the study Diabetes diagnosis in the last 15 years Adequacy of vitamin D serum level (Vit D3-25OH: 30-100 ng/mL)

Exclusion criteria

Exclusion criteria: pregnancy and breastfeeding history of kidney disease, kidney stone, liver disease, thyroid disease, cardiovascular disease, and cancer. special diets (raw vegetarianism, weight loss, etc.)

Design outcomes

Primary

Measure	Time frame
Bone formation marker (Osteocalcin). Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: Osteocalcin kit by ELISA method with ELISA reader device.;Bone resorption marker (CTX-1). Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: CTX-1 kit by ELISA method with ELISA reader device.;Fasting Blood Sugar. Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: Calorimetric method with autoanalyzer.;Insulin. Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: ELISA method, ELISA reader device.;HbA1c. Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: HPLC method and Agilent device.	—

Measure

Time frame

Bone formation marker (Osteocalcin). Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: Osteocalcin kit by ELISA method with ELISA reader device.;Bone resorption marker (CTX-1). Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: CTX-1 kit by ELISA method with ELISA reader device.;Fasting Blood Sugar. Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: Calorimetric method with autoanalyzer.;Insulin. Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: ELISA method, ELISA reader device.;HbA1c. Timepoint: At the beginning of the study (before the start of the intervention) and 12 weeks after the start of consumption. Method of measurement: HPLC method and Agilent device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMojtaba Akbari

Esfahan University of Medical Sciences

akbari.epi@gmail.com+98 31 3335 9933

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026